Table 3.
Deterministic, sensitivity and threshold results of the model for [68Ga]Ga-PSMA-11 PET/CT versus standard of care
| Incremental cost (€) | Incremental quality of life (QALY) | ICER (€/QALY) | Life years (years) | Net Monetary Benefit* | Incremental treatment cost (€) ** | Incremental treatment quality of life (QALY) ** | |
|---|---|---|---|---|---|---|---|
| Standard of care (ePLND)*** | € 35,659 | 10.271 | 15.25 | €15,586 | − 0.07 | ||
| Strategy | |||||||
| PSMA PET/CT ([68Ga]Ga-PSMA-11 PET/CT) | − € 674 | − 0.011 | €58,825 | - 0.02 | − € 243 | − € 757 | + 0.006 |
| Threshold analysis | |||||||
| N1ext by [68Ga]Ga-PSMA-11 PET/CT (FP) = 0.8% | − € 631 | 0.0003 | Dominant | − 0.005 | € 654 | − € 656 | + 0.005 |
| ePLND disutility = 0.052 | − € 674 | 0.0002 | Dominant | − 0.018 | € 694 | − € 757 | + 0.018 |
*Net monetary benefit was calculated using a willingness to pay of €80,000 per QALY, for both increase and decrease of quality of life. ePLND extended pelvic lymph node dissection, FP false positive, ICER Incremental cost-effectiveness ratio, IKNL the Netherlands Comprehensive Cancer Organisation, PET/CT positron emission tomography/computed tomography, PSMA prostate specific membrane antigen, QALY quality-adjusted life years.
**Results from the decision table for treatment costs and effects
***For standard of care, the absolute costs and effects are shown